MARKET

ORGO

ORGO

Organogenesis Holdings Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.830
0.000
0.00%
Closed 19:04 08/05 EDT
OPEN
--
PREV CLOSE
3.770
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
8.34
52 WEEK LOW
2.472
MARKET CAP
406.39M
P/E (TTM)
-8.8884
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ORGO stock price target is 7.50 with a high estimate of 8.00 and a low estimate of 7.00.

EPS

ORGO News

More
Organogenesis (ORGO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Organogenesis (ORGO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 2d ago
Latest Advanced Wound Care Innovations and Research from Organogenesis to be Highlighted at SAWC Spring | WHS 2020 Virtual Meeting
CANTON, Mass., July 23, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical & S
GlobeNewswire · 07/23 20:05
Organogenesis sees Q2 revenue above consensus
Organogenesis Holdings (NASDAQ:ORGO) expects Q2 net revenue between $68M - $68.6M vs. consensus of $48.25M and net revenue from PuraPly products between $2
seekingalpha · 07/15 16:40
Organogenesis Sees Prelim. Q2 Sales $68M-$68.6M
CANTON, Mass., July 15, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for
Benzinga · 07/15 11:32
Organogenesis Holdings Inc. Reports Preliminary Revenue Results for Second Quarter 2020
CANTON, Mass., July 15, 2020 -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and.
GlobeNewswire · 07/15 11:30
IPO Update: ACell Proposes $75 Million IPO Terms
Seeking Alpha - Article · 07/13 17:28
ACell Starts U.S. IPO Effort
Seeking Alpha - Article · 07/05 15:53
Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2020 Financial Results on August 10, 2020
GlobeNewswire · 06/29 12:30

Industry

Pharmaceuticals
+0.34%
Pharmaceuticals & Medical Research
+0.35%

Hot Stocks

Symbol
Price
%Change

About ORGO

Organogenesis Holdings Inc., formerly Avista Healthcare Public Acquisition Corp, is a regenerative medicine company. The Company focuses on the development, manufacture and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets. It also provides integrated healing solutions that substantially improve medical outcomes. The Company’s advanced wound care and surgical & sports medicine products include PuraPly, Antimicrobial (PuraPlyAM), PuraPly, Affinity, NuShield, Apligraf and Dermagraft. The Company is offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. The Company’s comprehensive portfolio is designed to treat a variety of patients with repair and regenerative needs.
More

Webull offers kinds of Organogenesis Holdings Inc stock information, including NASDAQ:ORGO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ORGO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ORGO stock methods without spending real money on the virtual paper trading platform.